Svb Leerink Reaffirms Outperform Rating for Centogene (NASDAQ:CNTG)

Svb Leerink restated their outperform rating on shares of Centogene (NASDAQ:CNTG) in a research note released on Monday, reports. Svb Leerink also issued estimates for Centogene’s Q3 2019 earnings at ($18.47) EPS, Q4 2019 earnings at ($0.18) EPS, FY2019 earnings at ($4.37) EPS, Q1 2020 earnings at ($0.25) EPS, Q2 2020 earnings at ($0.27) EPS, Q3 2020 earnings at ($0.26) EPS, Q4 2020 earnings at ($0.30) EPS, FY2020 earnings at ($1.09) EPS, Q1 2021 earnings at ($0.19) EPS, Q2 2021 earnings at ($0.17) EPS, Q3 2021 earnings at ($0.15) EPS and FY2021 earnings at ($0.61) EPS.

Other research analysts also recently issued reports about the stock. BTIG Research assumed coverage on shares of Centogene in a research note on Monday. They set a buy rating and a $18.00 price objective on the stock. Evercore ISI assumed coverage on shares of Centogene in a report on Monday. They set an outperform rating and a $17.00 price objective for the company. Finally, Robert W. Baird began coverage on shares of Centogene in a research report on Tuesday. They issued an outperform rating and a $15.00 target price for the company.

Shares of CNTG stock traded down $0.94 during mid-day trading on Monday, reaching $11.81. 544 shares of the company were exchanged, compared to its average volume of 63,300. Centogene has a fifty-two week low of $11.61 and a fifty-two week high of $15.59.

Centogene Company Profile

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.

See Also: Why do analysts give a neutral rating?

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with's FREE daily email newsletter.